Back to top

Hurricane Lane Mars Hawaiian Holdings August Traffic Data

Read MoreHide Full Article

Hawaiian Holdings, Inc.’s (HA - Free Report) wholly owned subsidiary, Hawaiian Airlines, reported disappointing traffic figures for August. Load factor declined in the month as traffic growth was outpaced by capacity expansion.

Traffic (measured in Revenue Passenger Miles or RPMs) increased 7.6% to 1.56 billion in the month.  Available Seat Miles (ASMs) also climbed 9.9% to 1.85 billion in the period. However, load factor (percentage of seats filled by passengers) contracted 180 basis points (bps) to 84.4%.

During the first eight months of 2018, the carrier recorded a 6% rise in RPMs while ASMs rose 5.9%. As a result, load factor inched up 10 bps. Additionally, passenger count increased 4.6% while the same slid 0.2% in August.

The decline in August passenger count can be attributed to adverse impacts of Hurricane Lane late in the month. The storm disrupted operations and induced soft bookings due to passengers cancelling flights. Consequently, the carrier trimmed guidance for third-quarter operating revenue per available seat mile (RASM). The airline now anticipates RASM in the range of -2 to 0% (year-over-year change). Earlier outlook was in the band of -1.5 to 1.5% (year-over-year change).

Zacks Rank & Key Picks

Hawaiian Holdings carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader Transportation sector are SkyWest, Inc (SKYW - Free Report) , C.H. Robinson Worldwide, Inc. (CHRW - Free Report) and Trinity Industries, Inc. (TRN - Free Report) . While C.H. Robinson holds a Zacks Rank #2 (Buy), SkyWest and Trinity sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of SkyWest, C.H. Robinson and Trinity have rallied more than 65%, 37% and 22%, respectively, in a year.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

More from Zacks Analyst Blog

You May Like